Clinic Software← All companies
Darwin Biosciences
Disease Detection Simplified
health AI / medtech / point-of-care diagnostics
StageSeed Round
Raised$699,406 (SBIR records) to $949,406 (SBIR + LinkedIn grant total)
Founded2020
Employees9
LocationBoulder, CO
About
Darwin Biosciences is redefining how infected individuals are detected by measuring an early immune response in saliva. Our hand-held device, developed in collaboration with the US Department of Defense and academic institutions, amplifies and detects human RNA in saliva that is broadly indicative of infection at the pre-symptomatic, asymptomatic, and symptomatic stages.
Founders
- Nicholas Meyerson — Co-Founder and CEO
- Qing Yang — Co-Founder & Scientific Consultant
Key features
Saliva-based samplingNon-invasive, point-of-care deviceDoes not require laboratory or power sourcesFast, accurate resultsDetects immune response to infection (pathogen-agnostic)Adaptable for nucleic acid detection across disease spacesEarly sepsis detectionMilitary-era inspired rapid, field-deployable diagnostics
Technologies
Biomarker panel for immune signatureSaliva-based samplingNucleic acid detectionPOC (point-of-care) diagnostic platform
Investors
University of Chicago New Venture Challenge
News
- Building Darwin Biosciences: 5 years of innovation and challenges · 2025-03-06T00:00:00.000Z
- Kyle Clark - Device Engineer | Diagnostic Platform Development · 2026-02-15T00:00:00.000Z
- Get a front-row seat to the University of Colorado's next big ideas... · 2025-09-24T00:00:00.000Z
- Colorado BioScience Association Strengthens Board Leadership to... · 2026-03-04T00:00:00.000Z
- Darwin AG | · 2026-03-18T10:00:04.000Z
